Seres Therapeutics Announces Topline Results For Ser 287 P Cambridge, mass. (business wire) jul. 22, 2021 seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced topline results from the phase 2b eco reset study evaluating ser 287 in patients with mild to moderate ulcerative colitis (uc). the study did not meet its primary endpoint of improving clinical. Seres therapeutics, inc., (nasdaq:mcrb) today announced positive topline results from a ser 287 phase 1b placebo controlled induction study in 58 patients with mild to moderate ulcerative colitis (uc), who were failing current therapies. study data demonstrate that ser 287, a microbiome therapy containing a consortium of live bacterial spores.
Seres Therapeutics Mcrb Ser 287 Phase 1b Topline Study Results I The company continues to conduct analyses on its ser 287 and ser 301 uc clinical stage programs to inform next steps for further development. based on the ser 287 phase 2b microbiome data analyses, engraftment of ser 287 bacteria was statistically significant in patients receiving ser 287 versus placebo (p ≤ 0.001 at all timepoints). Seres therapeutics announced positive topline results from the company’s phase 1b placebo controlled study investigating the effects of ser 287, a potential microbiome therapy, in patients with ulcerative colitis (uc) who failed to respond to current therapies. the study is ongoing and actively recruiting participants. Following the topline clinical data readout in july, which noted that the ser 287 phase 2b study did not achieve its primary endpoints, analysis of the microbiome data demonstrated the successful. Seres therapeutics, inc. (nasdaq: mcrb) today announced the publication of data analyses from the company’s phase 1b trial of ser 287 in patients with and we expect to obtain topline results.
Seres Therapeutics Mcrb Ser 287 Phase 1b Topline Study Results I Following the topline clinical data readout in july, which noted that the ser 287 phase 2b study did not achieve its primary endpoints, analysis of the microbiome data demonstrated the successful. Seres therapeutics, inc. (nasdaq: mcrb) today announced the publication of data analyses from the company’s phase 1b trial of ser 287 in patients with and we expect to obtain topline results. Seres therapeutics, inc., a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the phase 2 b eco reset study evaluating ser 287 in patients with. Cambridge, mass.–(business wire)–seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the phase 2b eco reset study evaluating ser 287 in patients with mild to moderate ulcerative colitis (uc). following the topline clinical data readout in july, which.
Seres Therapeutics Announces Initiation Of Ser 287 Phase 2b Eco Reset Seres therapeutics, inc., a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the phase 2 b eco reset study evaluating ser 287 in patients with. Cambridge, mass.–(business wire)–seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced preliminary microbiome data analyses from the phase 2b eco reset study evaluating ser 287 in patients with mild to moderate ulcerative colitis (uc). following the topline clinical data readout in july, which.
Comments are closed.